Skip to main content

Fiscal Wizard · Single-issue tearsheet

ORIC / Jun 21, 2026 Run #7419

ORIC

ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Composite verdict

F 22.5 / 100
Bearish setup · Reversal 6 drivers · 4 gates blocking
  • MA Rejection
  • Double 7s
  • Fibonacci Retracement
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 241st of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 10Mean-reversion Neutral 41

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -99%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

44.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 79
Margin of Safety 0
P/B 75
Free Cash Flow Yield 0
Return on Capital Employed 67
Return on Equity 25

Technicals Bearish

0.2 / 100

Bearish setup leads (MA Rejection, Double 7s, Fibonacci Retracement); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
MA Rejection 16
Double 7s 18
Fibonacci Retracement 23

Risk Gates

4 blocking 5 caution

4 guards active, 23 signals gated.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ORIC.